ANNOUNCED AS TEMPORARYNo
Decree No. 1045 regulates the procedure for allocation of subsidies from the federal budget of the Russian Federation to Russian organisation. Their purpose is to compensate part of the expenses for clinical trials of medical products as part of the framework of the state programme for the development of the pharmaceutical and medical production in the period 2013--2020.
The state subsidies under Decree No. 1045 are provided for the development of the innovative potential of the pharmaceutical industry in accordance with the priority directions of scientific research. The priority medicines that are subsidised under Decree No. 1045 are indicated in its article 3. They are for the treatment of cancer, autoimmune and neurodegenerative diseases, endocrine diseases, diabetes, cardiovascular diseases, infectious diseases, tuberculosis, HIV-infection and viral hepatitis.
The maximum subsidy may not exceed 200 million Russian Roubles (3.04 million USD) for the whole term of validity of a contract. An eligible beneficiary may receive a subsidy not more often than twice per year. Costs incurred not earlier than 1 January 2015 in the amount of not more than 50% of the cost for acquisition of raw materials, consumables, services of external organisations for research and transportation of clinical samples, etc. are eligible.
The provided official note that accompanies Decree No. 1045 states that it (together with other indicated as related state acts by the GTA) "will contribute to import substitution in the pharmaceutical and medical industries, will enhance the investment activity of the Russian organisations with the goal to create and modernise the production, will increase the share of domestically produced medicines and medical products, will create high-performance workplaces."
The GTA includes state guarantees and other financial incentives that are likely to affect the restructuring and performance of firms facing international competition, whether from imports, in export markets and from foreign subsidiaries.
⚑ Please report this page in case you detect an inaccuracy in its content.